Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

October 21, 2022

Amanda Cass, PharmD, BCPS, BCOP, discusses strategies to manage the diarrhea that may occur as an adverse effect in patients treated with EGFR TKIs.

October 21, 2022

Emily Skotte, MSN, discusses common ways to manage the rashes that may occur as adverse effects in patients treated with EGFR TKIs.

October 17, 2022

Wade T. Iams, MD, discusses the potential for providing small cell lung cancer subtyping in clinical practice.

October 11, 2022

Kelly Hewitt, MD, discusses treatment considerations for breast conservation vs mastectomy in breast cancer.

August 16, 2022

Kathryn E. Beckermann, MD, PhD, discusses the future of treatment in renal cell carcinoma.

August 08, 2022

The addition of fruquintinib to best supportive care improved overall survival compared with BSC alone in patients with metastatic colorectal cancer who progressed on standard chemotherapy and relevant biologic agents, and who had progressed on or were intolerant to trifluridine/tipiracil and/or regorafenib.

August 03, 2022

Vanderbilt University Medical Center and the University of Zambia are partnering on a program to develop a cadre of researchers and educators to lead cancer epidemiology research and training in Zambia and to encourage U.S.-based researchers to engage in cancer research in low- and middle-income countries.

July 14, 2022

Brian I. Rini, MD, and Matthew Tucker, MD, sit down to discuss developing a career path and building a résumé, the value of writing review articles early in fellowship, the power of saying no, and the importance of saying yes.

July 11, 2022

Most hematology/oncology fellows will care for patients with venous thromboembolism throughout their training and long after their graduation from fellowship. Here are some practical considerations when treating a patient with an acute VTE.

July 07, 2022

Ben Ho Park, MD, PhD, summarizes exciting data regarding circulating tumor DNA testing, including its ability to determine the benefits of adjuvant chemotherapy, its successful preliminary use in detecting cancer prior to recurrence, and how it may help guide future therapies.

June 04, 2022

Guided approaches leveraging circulating tumor DNA status can reduce the number of patients who receive adjuvant chemotherapy without the risk of lowering recurrence-free survival rates for some patients with stage II colon cancer.

March 01, 2022

Wade T. Iams, MD, discusses the key implications of the phase 3 ADAURA trial in non–small cell lung cancer.

February 03, 2022

January 12, 2022

Liquid biopsies are critical in understanding oncogenic drivers and resistance mechanisms in patients with non–small cell lung cancer.

January 10, 2022

Wade T. Iams, MD, discusses the need to establish the clinical utility of circulating tumor DNA testing in lung cancer.

January 07, 2022

Kristen K. Ciombor, MD, MSCI, discusses data evaluating the utility of rechallenging with EGFR inhibitors in RAS/RAF wild-type colorectal cancer.

January 04, 2022

With an influx of new trials examining the use of anti-EGFR treatments in patients with advanced colorectal cancer, attention must be paid to finding the optimal window in which to give these therapies to maximize benefit.

January 03, 2022

Dr Gilbert discusses her new role as associate director for research, education, and professional development at Vanderbilt University Medical Center and shares some of her short- and long-term goals in this position.

December 20, 2021

Kristen K. Ciombor, MD, MSCI, discusses the use of panitumumab in the maintenance treatment of patients with RAS wild-type metastatic colorectal cancer.

November 16, 2021

Kristen K. Ciombor, MD, MSCI, discusses the use of anti-EGFR therapy for the frontline treatment of patients with metastatic colorectal cancer.